Christian Marth, MD, PhD, and Bradley J. Monk, MD, FACS, FACOG, discuss data from the NRG GY018 and RUBY trials regarding the use of immunotherapies for the treatment of endometrial cancer.
Eugenia Girda, MD, FACOG, discusses the use of pembrolizumab plus chemotherapy for patients with endometrial cancer as seen in the phase 3 NRG-GY018 trial.